ENTRY       D12293                      Drug
NAME        Inclisiran sodium (JAN);
            Leqvio (TN)
PRODUCT     LEQVIO (Novartis Pharmaceuticals Corporation)
FORMULA     C529H664F12N176O316P43S6. 43Na
EXACT_MASS  17276.375
MOL_WEIGHT  17284.7247
CLASS       Hypolipidemic agent
             DG01946  Hypolipidemic agent
              DG03128  Anti-PCSK9 antibody and siRNA
REMARK      Therapeutic category: 2189
            ATC code: C10AX16
            Chemical structure group: DG03216
            Product (DG03216): D12293<JP/US>
EFFICACY    Antihyperlipidemic, Translation inhibitor
  DISEASE   Heterozygous familial hypercholesterolemia [DS:H00155]
            Atherosclerotic cardiovascular disease [DS:H02505]
  TYPE      RNA interference (RNAi) drug
TARGET      PCSK9 [HSA:255738] [KO:K13050]
  PATHWAY   hsa04979(255738)  Cholesterol metabolism
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C10 LIPID MODIFYING AGENTS
               C10A LIPID MODIFYING AGENTS, PLAIN
                C10AX Other lipid modifying agents
                 C10AX16 Inclisiran
                  D12293  Inclisiran sodium (JAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Cardiovascular Agents
              Dyslipidemics, Other
               Inclisiran
                D12293  Inclisiran sodium (JAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               218  Hyperlipidemia agents
                2189  Others
                 D12293  Inclisiran sodium (JAN)
            Drug groups [BR:br08330]
             Hypolipidemic agent
              DG01946  Hypolipidemic agent
               DG03128  Anti-PCSK9 antibody and siRNA
                DG03216  Inclisiran
                 D12293  Inclisiran sodium
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG01946  Hypolipidemic agent
               D12293  Inclisiran sodium
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                PCSK9
                 D12293  Inclisiran sodium (JAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12293
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12293
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12293
            Drug groups [BR:br08330]
             Hypolipidemic agent
              DG01946  Hypolipidemic agent
               DG03128  Anti-PCSK9 antibody and siRNA
                DG03216  Inclisiran
DBLINKS     CAS: 1639324-62-1
///
